Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of January 2022, with the report dated January 3, 2022. The document serves to disclose specific changes in the company's management structure.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the restructuring of senior management roles:
- Appointment: Mr. Sassi Masliah will be appointed Executive Vice President of Corporate Development, effective February 1, 2022. He has been with Evogene for 11 years, most recently serving as Vice President for Legal Affairs and Corporate Secretary.
- Departure: Mr. Lazer Bezdin will conclude his position as Chief Operating Officer, effective March 2, 2022.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the announcement of the management changes noted above.
Key Facts for Investor Verification
- Verify the effective dates for the new Executive Vice President (February 1, 2022) and the departing Chief Operating Officer (March 2, 2022).
- Confirm the interim leadership structure for the Corporate Development and Operations functions during the transition period.
- Note that this filing does not contain financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial data.